Galaxy Securities lasted more than two months, and carried out an in-depth and comprehensive analysis of the policy environment of the genetic sequencing industry, technology trends and business models and investment logic of the industry giants, and released the development trend and business model of gene sequencing - exploring precision medicine An in-depth research report on (1) of the series report. Foreign companies are strategic and systematic in the field of gene sequencing. Each company relies on its inherent talents to extend upstream or downstream to consolidate its own industry barriers. 23andMe focuses on reducing the price to collect human genome samples for subsequent collaboration with pharmaceutical companies; Illumina enters the midstream and downstream markets while consolidating the dominance of NGS sequencing; Roche focuses on the development and acquisition of third and fourth generation sequencing, while opening up the middle and lower reaches; Google leverages the strengths of Internet companies to collect genomic samples by developing cloud storage analytics. 23andMe: Collecting genomic data in large quantities and entering the field of drug research and development 23andMe is a startup that provides gene sequencing services, providing ancestral analysis, talent analysis and health testing services. The service process is very convenient. After the customer purchases the product, he receives the sample collection box of the company's direct mail. After the saliva sample is collected, it is sent back to the company for testing. From the beginning of 2006, to the end of 2013, the health testing service was stopped, and now it is a good inspiration to explore the overseas market to restore the corresponding services and develop drug development. Figure 27. 23andMe development major events 23andMe captures nearly a million consumer data at significantly lower than the test price of its competitors, aiming to build the world's largest database of genetic information. The 23andMe, deCODE, and Navigenics companies offer higher-overlapping services, with the asking price of $399, $985, and $2,499, respectively. 23andMe attracts a large number of consumers to detect with its obvious price advantage and partial entertainment consumption pattern. Currently, it has accumulated hundreds of thousands of consumer data. In order to collect more genomic data, 23andMe mainly reduces the cost of sequencing by two means: (1) only detecting single nucleotide polymorphism (SNP) during sequencing, not using whole genome sequencing; (2) reducing detection price through financing subsidy : After the round B and C round of financing (a total of 50 million US dollars), the test price is 299 US dollars; after the D round of financing (50 million US dollars), the price is 99 US dollars; is currently preparing 150 US dollars of E round financing, has completed 7910 In the case of tens of thousands of dollars in financing, it is widely speculated that the sequencing price will be further reduced. 23andMe also collects genomic data by actively exploring the European and American markets. Following the FDA's suspension of health testing services in 2013, 23andMe's personal health testing service was approved by UK regulators in early 2015 to launch personal genome services on the Superdrug website and its more than 600 physical stores in the UK to provide personal health and family genetic diseases. Information on the aspect. At the same time, in February 2015, 23andMe's relationship with the FDA also regained its good, and its genetic testing products for detecting Bloom's syndrome were re-approved by the FDA. After collecting enough genomic samples, 23andMe turned to drug development. Currently 23andMe has completed more than 1 million tests, although the total operating income is less than $200 million. However, the large sample database in its hands has been regarded as a Chinese meal by biopharmaceutical companies. 23andMe's main line of sales became aggregated consumer gene data for sale to pharmaceutical or biotech companies, which used this information to guide drug development: In January 2015, 23andMe signed a $60 million agreement with Roche's Genentech. The two companies will jointly analyze the genome sequencing data of 3,000 patients with Parkinson's disease to find a new treatment for this neurodegenerative disease. Subsequent to Pfizer's collaboration, 23andMe allowed Pfizer to access its research platform, including 23andMe's services and genetic data analysis for more than 800,000 people. In the early stages of collaboration, Pfizer will study the genomic data of 5,000 lupus patients from 23andMe to learn more about lupus genes. At the same time, in early March 2015, 23andMe announced the formation of a new pharmaceutical company focused on identifying and developing new treatments for the disease, marking the company's advancement in drug development. Roche: Layout of three or four generations of sequencing, synergistic development of pharmaceuticals, diagnostics and devices to build precise medical barriers Founded in October 1896, Roche is a multinational company based on research and development, mainly in the fields of medicine, medical diagnosis, vitamins and fine chemicals, flavors and fragrances. Roche Pharmaceuticals provides internationally advanced research and development of oncology drugs, and its anti-cancer drugs are in a dominant position. Roche Diagnostics provides sequencing products and services, and provides a basis for sequencing new drug development while arranging future development. Roche has spanned the field of drug discovery and gene sequencing. After the second-generation sequencing instrument Roche 454 market share was occupied by Illuima, Roche launched a new layout in the field of gene sequencing. Table 11. Roche's business model in the field of gene sequencing Feed Additive Corn Gluten Feed Additive Corn Gluten Feed,Wet Corn Gluten Feed,Custom Corn Gluten Feed,Dairy Cows Corn Gluten Feed JILIN COFCO BIO-CHEM AND BIO-ENERGY MARKETING CO., LTD , https://www.cofco-biotech.com.png)
.png)